

# Guiding Light

## Oncology Nurses' Vital Role in Supporting Patients Through CLL Therapy



**Saturday, April 27, 2024**

5:30 PM ET Registration & Dinner Buffet

6:00-7:30 PM ET Presentation

**Marriott Marquis**

Salons 1-4

Meeting Level 2



*Meeting space has been assigned to provide a symposium supported by BeiGene USA, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. - both are Johnson & Johnson companies; and Lilly and presented by Creative Educational Concepts during the Oncology Nursing Society's (ONS) 49th Annual Congress, April 24 – April 28, 2024 in Washington, D.C. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.*

# Guiding Light

## Oncology Nurses' Vital Role in Supporting Patients Through CLL Therapy

### Activity Description

More than 200,000 people in the United States are living with a chronic lymphocytic leukemia (CLL) diagnosis, and it is responsible for approximately 4,410 U.S. deaths each year. The treatment landscape for CLL has changed dramatically in the past 10 years and there are now four FDA-approved Bruton tyrosine kinase inhibitors (BTKis), as well as venetoclax and chemoimmunotherapies, available to clinicians for their patients in the United States, while new, second- and third-generation BTKis and novel combination therapies are emerging. As a result, oncology nurses will be required to navigate varying dosing regimens and adverse event (AE) management approaches with their patients, in order to maximize therapy adherence.

In this Creative Educational Concepts (CEC) live symposium, expert faculty will discuss strategies for differentiating patient- and disease-specific variables that inform CLL treatment selection, developing plans for managing new AEs, and addressing patient-related treatment barriers to improve adherence to CLL therapy.

### Target Audience

Oncology nurse practitioners (NPs) and RNs (academic and community)

### Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Differentiate patient- and disease-specific variables that inform CLL treatment selection
- Develop plans for managing AEs arising from new and emerging CLL treatment approaches, as well as long-term and late effects of treatments
- Incorporate strategies to address patient-related treatment barriers to improve adherence to CLL therapy

### Faculty

#### **Amy L. Goodrich, RN, BSN, MSN, CRNP-AC (Moderator)**

*Nurse Practitioner*

*The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins*

*Division of Hematologic Malignancies*

*Baltimore, MD*

#### **Nikki Barkett, BSN, RN, OCN**

*Patient Access*

*Coordinator V*

*Banner University of Arizona Cancer Center*

*Tucson, AZ*

#### **Matthew S. Davids, MD, MMSc**

*Clinical Research Director, Division of Lymphoma*

*Dana-Farber Cancer Institute*

*Associate Professor of Medicine*

*Harvard Medical School*

*Boston, MA*

# Guiding Light

## Oncology Nurses' Vital Role in Supporting Patients Through CLL Therapy

### Accreditation

#### Jointly Accredited Provider



In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Nurses (ANCC)



This activity is designated for 1.5 contact hours.

#### Pharmacotherapy

ANCC definition of pharmacotherapeutic content is that it may include but is not limited to drug specific information, safe prescribing practices, safe medication administration, prescribing methodologies, new regulations, or similar content.

#### Note to Nurse Practitioners

The content of this CNE activity pertains to Pharmacology.

#### Oncology Nursing Certification (ONCC) [ILNA]



The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

**OCN®** - Oncology Nursing Practice (Scientific Basis/Profession), Symptom Management & Palliative Care, Psychosocial Dimensions of Care

**AOCNP®/AOCNS®** - Cancer Treatment, Side Effect & Symptom Management, Psychosocial Issues, Professional Practice

**CPHON®** - Cancer Treatment, Side Effect & Symptom Management, Psychosocial Issues

**BMTCN®** - Professional Performance

**CBCN®** - Nursing Practice (Symptom Management, EoL Care, Professional), Psychosocial & Spiritual

*Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.*

# Guiding Light

## Oncology Nurses' Vital Role in Supporting Patients Through CLL Therapy

### Faculty



#### **Amy L. Goodrich, RN, BSN, MSN, CRNP-AC (Moderator)**

*Nurse Practitioner*

*The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins*

*Division of Hematologic Malignancies*

*Baltimore, MD*

Amy Goodrich, RN, BSN, MSN, CRNP-AC, Research Associate, is a Nurse Practitioner in the Hematologic Malignancies Program and Research Nursing Manager at The Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland. Ms. Goodrich manages patients with various types of hematologic malignancies, concentrating on the lymphomas. She also manages the Cancer Center's research nurses and is extremely involved in research operations.

Ms. Goodrich earned her master's degree in 2000 as an Acute Care Nurse Practitioner from the Johns Hopkins University and her undergraduate nursing degree from the University of Pittsburgh.

Ms. Goodrich reports the following financial relationships:

Advisory Board: Abbvie Inc.; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

# Guiding Light

## Oncology Nurses' Vital Role in Supporting Patients Through CLL Therapy

### Faculty



#### **Nikki Barkett, BSN, RN, OCN**

*Patient Access*

*Coordinator V*

*Banner University of Arizona Cancer Center*

*Tucson, AZ*

Nikki Barkett, BSN, RN, OCN, is a Patient Access Coordinator V at Banner University of Arizona Cancer Center. She earned her bachelor's degree in nursing at the California State University, Chico. She relies on her more than 30 years of oncology nursing experience to guide her practice. She is a member of Oncology Nursing Society (ONS), Academy of Oncology Nurse and Patient Navigators (AONN+), and Association of Community Cancer Centers (ACCC). She has also served as co-chair of the AONN+ CAPE CLL Initiative.

Ms. Barkett reports no financial relationships to disclose.

# Guiding Light

## Oncology Nurses' Vital Role in Supporting Patients Through CLL Therapy

### Faculty



#### **Matthew S. Davids, MD, MMSc**

*Clinical Research Director, Division of Lymphoma  
Dana-Farber Cancer Institute  
Associate Professor of Medicine  
Harvard Medical School  
Boston, MA*

Matthew S. Davids, MD, MMSc, is an associate professor of medicine at Harvard Medical School in Boston, Massachusetts. He is the clinical research director in the Division of Lymphoma at Dana-Farber Cancer Institute in Boston as well as the leader of the Lymphoma Program for Dana-Farber/Harvard Cancer Center. In addition to maintaining a busy clinical practice focused mainly on chronic lymphocytic leukemia (CLL), Dr. Davids leads numerous clinical trials of novel combination regimens for patients with CLL and lymphoma. He also runs an independent laboratory that utilizes functional precision medicine techniques to study patient samples, with a goal of predicting responses to therapy and understanding resistance mechanisms to targeted therapies.

Dr. Davids reports the following financial relationships:

**Consultant:** AbbVie Inc.; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Meyer Squibb Company; Lilly; Genentech, Inc.; GENMA Pharma; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Nuvalent; Secura Bio, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TG Therapeutics, Inc.

# Guiding Light

## Oncology Nurses' Vital Role in Supporting Patients Through CLL Therapy

### Disclosure Declarations

It is the policy of Creative Educational Concepts LLC (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers' bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

#### Peer Reviewers

**Alaa Bawaneh, MD, PhD**—no disclosures to report.

**Albert Eubanks, Jr., RN**—no disclosures to report.

#### CEC Staff/Planners

**Evan Luburger**—no disclosures to report.

**Katherine Lee, PharmD**—no disclosures to report.

**Sandra Caballero, PharmD**—no disclosures to report.


**Scott J. Hershman, MD, FACEHP, CHCP**—no disclosures to report.

**Sharon Tordoff**—no disclosures to report.

**Faculty of this CME/CE activity** may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

# Guiding Light

## Oncology Nurses' Vital Role in Supporting Patients Through CLL Therapy



### Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

#### ASK FACULTY A QUESTION

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

#### VIEW AND TAKE NOTES ON PRESENTATION SLIDES

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

### Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to create an account.



### Downloadable Resources

Downloadable resources will be available at [ceconcepts.com/CLLresources](https://ceconcepts.com/CLLresources).

### Engage with Us

Follow us [@creative.educational.concepts](https://twitter.com/creative.educational.concepts) for announcements about upcoming CME opportunities, healthcare news, and more!



*Thank you for joining us today!*